Latest

Rita Hayworth and Alzheimer’s Redemption

With next month designated National Alzheimer’s Disease and Awareness Month in the US, Julian Upton looks at the film star whose plight pushed the long-misunderstood disorder into the spotlight.

CPhI Pharma Awards 2015: The Winners

Pharm Exec Editor-in-Chief William Looney was on hand to present the CPhI/PharmaBoardroom Award for CEO of the Year at a ceremony in Madrid, Spain, last night.

New & Noteworthy

Rewriting the Book of Life: A New Era in Precision Gene Editing

Advances in gene-editing technology have the potential to fundamentally reshape vital treatments for patients. The path of progress, however, will hinge on the ability of drugmakers to choose the right technology and partner.

Knowledge is Value: Navigating Biopharma’s New IP Terrain

With GE’s blueprint for effective IP engagement as a guide, Thaddeus Burns explains how life sciences companies are using IP as a GPS to market relevance.

Competitive Trial Management: Winning with Clinical Studies

Savvy companies are leveraging clinical trials as competitive weapons in the larger brand wars, writes Stan Bernard.

Licensing Approval in Europe: New Options for a New Era

Leela Barham talks with the EMA's top medical officer, Hans-Georg Eichler, about a potentially game-changing drug approval program.

Biosimilars, Patent Issues Dominate Political Landscape

Managing the nomination of new commissioner adds to a packed agenda for FDA this month, writes Jill Wechsler.

From the Editor

Competition: The Best Defense

A new and more compelling strategy must be crafted to engage critics on drug pricing and bolster biopharmaceuticals as a leader in technological innovations that lower health costs overall. William Looney reports.

Audit Alliterations

A closer look at this year's Industry Audit numbers hints to a clear divide between two alternative strategies for long-term growth: scale versus focus. William Looney comments.

Europe

Licensing Approval in Europe: New Options for a New Era

Leela Barham talks with the EMA's top medical officer, Hans-Georg Eichler, about a potentially game-changing drug approval program.

High Hopes for England's Accelerated Access Review

No-one can say England's Accelerated Access Review, which aims to “ensure that the UK is the fastest place in the world for the design, development and widespread adoption of medical innovations" isn't aiming high, writes Leela Barham.

Global

What Makes a Good Patient Advocacy Strategy in Russia and CIS?

Nick Hicks looks at the challenges of devising a patient advocacy strategy amid the complex political, cultural and regulatory landscape of Russia and CIS.

China Resilient: New Pharma Survey Offers Highly Positive Outlook

A new trade expo survey predicts that it is full speed ahead for a market now too big to be ignored, writes Cameron Sharp.

PEspeaks

Hillary’s History on Rx Price Controls

Hillary Clinton has been a part of the healthcare debate since the early 90's. Tom Norton analyzes a of positions on drug price control and what it could mean for her candidacy.

Scaling the Limits of Scale: The PBM Path to Value-Based Healthcare

Scale has its limits, as the nation’s two largest pharmacy benefit managers (PBM), Express Scripts and CVS Caremark, are discovering. Stephen Littlejohn reports.

Competition: The Best Defense

A new and more compelling strategy must be crafted to engage critics on drug pricing and bolster biopharmaceuticals as a leader in technological innovations that lower health costs overall. William Looney reports.

Strategy

ThinkLive 2015: The Importance of Forward-Facing Collaboration

AmerisourceBergen believes the power of community begins with talk that gets the blood flowing.

Harnessing Digital to Construct New Business Models

Life sciences companies must go beyond digitizing individual operations, and instead harness digital to design and construct entirely new business models, writes Brags Srinivasan.

Expanded Access: Get Ready

While the initiation and management of an access program can be challenging and requires careful assessment and planning, the benefits to patients, healthcare providers and sponsoring companies are immeasurable, writes Rob Fox.

Regulatory

Licensing Approval in Europe: New Options for a New Era

Leela Barham talks with the EMA's top medical officer, Hans-Georg Eichler, about a potentially game-changing drug approval program.

Biosimilars, Patent Issues Dominate Political Landscape

Managing the nomination of new commissioner adds to a packed agenda for FDA this month, writes Jill Wechsler.

Europe: Small Steps Toward Big Changes in Drug Pricing

Reflector outlines the current measures European countries are working or collaborating on to achieve a better understanding of pricing issues.

Sales & Marketing

Bigger than Brand: Portfolio Positioning for Pharma

Jenna Earl outlines the three most important things to understand about portfolio positioning in pharma.

Pharma’s Prescription for Social ROI

Peter Friedman discusses five ways brand teams can find value in social media programs.

Syncing Personalized Medicine and Marketing

The new generation of individualized treatments will require life sciences companies to evolve how they reach and educate the healthcare community. Matt Wallach asks, are your commercial operations up to the task?

R&D;

‘Systems’ Spark Sought for Clinical Trials

The Alliance for Clinical Research Excellence and Safety (ACRES) is advocating a “systems thinking” approach in efforts to meet increasing demands to standardize and integrate support for trial sites. Casey McDonald reports.

Relationship-Centric Technology: Improving the Human Experience for Better Engagement

Relationship-centric technology presents a sizable emerging opportunity for sponsors to improve the performance of clinical development, writes Tom O'Leary.